SML0216
Brinzolamide
≥98% (HPLC)
동의어(들):
(5R)-5-Ethylamino-3-(3-methoxypropyl)-2,2-dioxo-2?6,9-dithia-3-azabicyclo[4.3.0]nona-7,10-diene-8-sulfonamide, (R)- 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-Thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide, AL 4862
로그인조직 및 계약 가격 보기
모든 사진(1)
About This Item
실험식(Hill 표기법):
C12H21N3O5S3
CAS Number:
Molecular Weight:
383.51
MDL number:
UNSPSC 코드:
12352200
PubChem Substance ID:
NACRES:
NA.77
추천 제품
Quality Level
분석
≥98% (HPLC)
양식
powder
저장 조건
desiccated
색상
white to beige
solubility
DMSO: ≥10 mg/mL
저장 온도
−20°C
SMILES string
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O
InChI
1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1
InChI key
HCRKCZRJWPKOAR-JTQLQIEISA-N
유전자 정보
human ... CA2(760)
유사한 제품을 찾으십니까? 방문 제품 비교 안내
일반 설명
Brinzolamide is a small molecular weight compound that has an ability to bind melanin. This drug is used in ocular therapy.
애플리케이션
Brinzolamide has been used as a melanin binding compound or drug in melanin binding assays. It has also been used as a carbonic anhydrase inhibitor (CAI).
생화학적/생리학적 작용
Brinzolamide is a carbonic anhydrase II inhibitor
Brinzolamide is a carbonic anhydrase II inhibitor used to lower intraocular pressure.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
이미 열람한 고객
Gemma Caterina Maria Rossi et al.
Expert opinion on pharmacotherapy, 12(5), 685-690 (2011-03-10)
To examine the impact of switching glaucoma patients from timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination (Brinz/Tim FC) on quality of life and on ocular surface status; to assess efficacy after the switch. 6-month, multicenter, open-label, prospective, switch study
To Be or Not to Be Protonated: Atomic Details of Human Carbonic Anhydrase-Clinical Drug Complexes by Neutron Crystallography and Simulation.
Kovalevsky A, et al.
Structure, 26(3), 383-390 (2018)
Gemma Caterina Maria Rossi et al.
Expert opinion on pharmacotherapy, 12(16), 2425-2431 (2011-06-18)
To assess ocular surface status and tolerability after switching glaucoma patients from dorzolamide/timolol to brinzolamide/timolol fixed combination (FC). Six-month, multicenter, open-label, prospective study that switched 72 patients from dorzolamide/timolol to brinzolamide/timolol FC. Intraocular pressure (IOP), tear film break-up-time (TF-BUT), fluorescein
John H K Liu et al.
Ophthalmology, 118(10), 1995-2000 (2011-06-17)
A core assumption for the 1-eye therapeutic trial of ocular hypotensive medications is the symmetrical reduction of intraocular pressure (IOP) in paired eyes. This assumption was evaluated for 24-hour IOP reduction in patients who underwent monotherapy or adjunctive therapy. Database
Louis F Dell'osso et al.
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 31(3), 228-233 (2011-06-29)
Recent advances in infantile nystagmus syndrome (INS) surgery have uncovered the therapeutic importance of proprioception. In this report, we test the hypothesis that the topical carbonic anhydrase inhibitor (CAI) brinzolamide (Azopt) has beneficial effects on measures of nystagmus foveation quality
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.